Dr. Craig H. Moskowitz, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 101
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Wayne State University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME135617 · NY license 179435
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 101
- Services billed
- 296
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 158 | 88 |
| Established patient office or other outpatient visit, 40-54 minutes | 74 | 46 |
| Established patient office or other outpatient visit, 20-29 minutes | 17 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Miami, FL | 58 |
| Brukinsa (zanubrutinib) | 42 |
| Prednisone Other prescribers in Miami, FL | 29 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Miami, FL | 23 |
| Calquence (acalabrutinib maleate) | 14 |
| Atovaquone | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $16,765 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $9,598 |
|---|---|
| Pfizer Inc. | $4,395 |
| Incyte Corporation | $2,055 |
| AbbVie Inc. | $363 |
| Janssen Scientific Affairs, LLC | $180 |
| Medtronic, Inc. | $173 |
| Compensation for services other than consulting (speaking, faculty) | $9,298 |
|---|---|
| Consulting Fee | $7,038 |
| Food and Beverage | $429 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $5,493 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 11, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $3,806 |
| Pfizer Inc. Jul 2, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $2,160 |
| Pfizer Inc. Jun 24, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $2,160 |
| Incyte Corporation May 29, 2025 | Consulting Fee | $2,055 |
| AbbVie Inc. Jul 14, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $363 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 17, 2025 | Consulting Fee | $300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $524,611 in research payments for these studies, mostly to the institutions running them.
- A phase 1 openlabel study to evaluate SGN35C in adults with advanced malignancies
Pfizer Inc. - Pembrolizumab and Site Radiation Therapy for Early Stage Hodgkin Lymphoma
Merck Sharp & Dohme LLC - An openlabel phase 1 study to evaluate the safety of SGN35T in adults with advanced malignancies
Pfizer Inc. - C4811001 study name not available yet
Pfizer Inc. - HD12 a randomized phase iii trial with a pet response adapted design comparing abvd rt with A2VD rt in patients with previously untreated stages iaiia hodgkin lymphoma
Pfizer Inc. - A Phase I/IIa, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.